BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 22925884)

  • 1. D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function.
    Sasaki M; Knobbe CB; Itsumi M; Elia AJ; Harris IS; Chio II; Cairns RA; McCracken S; Wakeham A; Haight J; Ten AY; Snow B; Ueda T; Inoue S; Yamamoto K; Ko M; Rao A; Yen KE; Su SM; Mak TW
    Genes Dev; 2012 Sep; 26(18):2038-49. PubMed ID: 22925884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in Fibrosarcoma Sells.
    Badur MG; Muthusamy T; Parker SJ; Ma S; McBrayer SK; Cordes T; Magana JH; Guan KL; Metallo CM
    Cell Rep; 2018 Oct; 25(4):1018-1026.e4. PubMed ID: 30355481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1
    Waitkus MS; Pirozzi CJ; Moure CJ; Diplas BH; Hansen LJ; Carpenter AB; Yang R; Wang Z; Ingram BO; Karoly ED; Mohney RP; Spasojevic I; McLendon RE; Friedman HS; He Y; Bigner DD; Yan H
    Cancer Res; 2018 Jan; 78(1):36-50. PubMed ID: 29097607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-Hydroxyglutarate-Mediated Autophagy of the Endoplasmic Reticulum Leads to an Unusual Downregulation of Phospholipid Biosynthesis in Mutant IDH1 Gliomas.
    Viswanath P; Radoul M; Izquierdo-Garcia JL; Ong WQ; Luchman HA; Cairncross JG; Huang B; Pieper RO; Phillips JJ; Ronen SM
    Cancer Res; 2018 May; 78(9):2290-2304. PubMed ID: 29358170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia.
    Reitman ZJ; Duncan CG; Poteet E; Winters A; Yan LJ; Gooden DM; Spasojevic I; Boros LG; Yang SH; Yan H
    J Biol Chem; 2014 Aug; 289(34):23318-28. PubMed ID: 24986863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system.
    Linninger A; Hartung GA; Liu BP; Mirkov S; Tangen K; Lukas RV; Unruh D; James CD; Sarkaria JN; Horbinski C
    Neuro Oncol; 2018 Aug; 20(9):1197-1206. PubMed ID: 29660019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities.
    Cairns RA; Mak TW
    Cancer Discov; 2013 Jul; 3(7):730-41. PubMed ID: 23796461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low pH Facilitates Heterodimerization of Mutant Isocitrate Dehydrogenase IDH1-R132H and Promotes Production of 2-Hydroxyglutarate.
    Sesanto R; Kuehn JF; Barber DL; White KA
    Biochemistry; 2021 Jun; 60(25):1983-1994. PubMed ID: 34143606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional requirement of a wild-type allele for mutant IDH1 to suppress anchorage-independent growth through redox homeostasis.
    Tiburcio PDB; Xiao B; Berg S; Asper S; Lyne S; Zhang Y; Zhu X; Yan H; Huang LE
    Acta Neuropathol; 2018 Feb; 135(2):285-298. PubMed ID: 29288440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and characterization of a novel mutant isocitrate dehydrogenase 1 inhibitor for glioma treatment.
    Zhang N; Zheng B; Yao X; Huang X; Du J; Shen Y; Huang Z; Chen J; Lin Q; Lan W; Lin W; Ma W
    Biochem Biophys Res Commun; 2021 Apr; 551():38-45. PubMed ID: 33714758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency.
    Avellaneda Matteo D; Grunseth AJ; Gonzalez ER; Anselmo SL; Kennedy MA; Moman P; Scott DA; Hoang A; Sohl CD
    J Biol Chem; 2017 May; 292(19):7971-7983. PubMed ID: 28330869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation.
    Lazovic J; Soto H; Piccioni D; Lou JR; Li S; Mirsadraei L; Yong W; Prins R; Liau LM; Ellingson BM; Cloughesy TF; Lai A; Pope WB
    Neuro Oncol; 2012 Dec; 14(12):1465-72. PubMed ID: 23090985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics.
    Sasaki M; Knobbe CB; Munger JC; Lind EF; Brenner D; Brüstle A; Harris IS; Holmes R; Wakeham A; Haight J; You-Ten A; Li WY; Schalm S; Su SM; Virtanen C; Reifenberger G; Ohashi PS; Barber DL; Figueroa ME; Melnick A; Zúñiga-Pflücker JC; Mak TW
    Nature; 2012 Aug; 488(7413):656-9. PubMed ID: 22763442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IDH1-mutated transgenic zebrafish lines: An in-vivo model for drug screening and functional analysis.
    Gao Y; de Wit M; Struys EA; van der Linde HCZ; Salomons GS; Lamfers MLM; Willemsen R; Sillevis Smitt PAE; French PJ
    PLoS One; 2018; 13(6):e0199737. PubMed ID: 29953513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitor potency varies widely among tumor-relevant human isocitrate dehydrogenase 1 mutants.
    Avellaneda Matteo D; Wells GA; Luna LA; Grunseth AJ; Zagnitko O; Scott DA; Hoang A; Luthra A; Swairjo MA; Schiffer JM; Sohl CD
    Biochem J; 2018 Oct; 475(20):3221-3238. PubMed ID: 30249606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.
    Jin G; Reitman ZJ; Duncan CG; Spasojevic I; Gooden DM; Rasheed BA; Yang R; Lopez GY; He Y; McLendon RE; Bigner DD; Yan H
    Cancer Res; 2013 Jan; 73(2):496-501. PubMed ID: 23204232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity.
    Liu Z; Yao Y; Kogiso M; Zheng B; Deng L; Qiu JJ; Dong S; Lv H; Gallo JM; Li XN; Song Y
    J Med Chem; 2014 Oct; 57(20):8307-18. PubMed ID: 25271760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1).
    Kang CH; Choi SU; Son YH; Lee HK; Jeong HG; Yun CS; Ahn S; Park CH
    Anticancer Res; 2020 Sep; 40(9):4929-4935. PubMed ID: 32878781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abundance of d-2-hydroxyglutarate in G2/M is determined by FOXM1 in mutant IDH1-expressing cells.
    Bala Bhaskara Rao K; Katragunta K; Sarma UM; Jain N
    FEBS Lett; 2019 Aug; 593(16):2177-2193. PubMed ID: 31211872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH1 mutation contributes to myeloid dysplasia in mice by disturbing heme biosynthesis and erythropoiesis.
    Gu Y; Yang R; Yang Y; Zhao Y; Wakeham A; Li WY; Tseng A; Leca J; Berger T; Saunders M; Fortin J; Gao X; Yuan Y; Xiao L; Zhang F; Zhang L; Gao G; Zhou W; Wang Z; Mak TW; Ye J
    Blood; 2021 Feb; 137(7):945-958. PubMed ID: 33254233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.